Coherus’s Receives the US FDA’s Approval of CHS-1420 (biosimilar, adalimumab) for the Treatment of Chronic Plaque Psoriasis
Shots:
- The approval is based on a (CHS-1420-02) study to evaluate the efficacy, safety & immunogenicity of Yusimry vs Humira in 545 subjects with moderate to severe chronic PsO
- The results showed that Yusimry was equivalent to adalimumab based on the 1EPs, 75% improvement in PASI-75 @12wks. Additionally, the CHS-1420-03 trial assessed the PK bioequivalence of Yusimry vs Humira after SC administration of a single (40mg) dose & demonstrated similarity on all PK endpoints
- Yusimry is Coherus' second FDA-approved product & is expected to launch in the US on July 2023, under the collaboration with AbbVie
Ref: Globe Newswire | Image: Coherus
Click here to read the full press release
This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com